Search Results - "Idris, Tazeen A."

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer by Owen, Joel S., Rackley, Russell J., Hummel, Matthew A., Roepcke, Stefan, Huang, Hannah, Liu, Mark, Idris, Tazeen A., Murugesan, Sundara Moorthi Nainar, Marwah, Ashwani, Loganathan, Subramanian, Ranganna, Gopinath, Barve, Abhijit, Waller, Cornelius F., Socinski, Mark A.

“…Background and Objectives MYL-1402O is a bevacizumab (Avastin ® ) biosimilar. Pharmacokinetic and safety similarity of MYL-1402O and reference Avastin ®…”
Get full text

Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC) by Owen, Joel, Rackley, Russell J., Hummel, Matthew A., Roepcke, Stefan, Huang, Hannah, Liu, Mark S., Idris, Tazeen A., Nainar Murugesan, Sundara Moorthi, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Ranganna, Gopinath, Barve, Abhijit J., Waller, Cornelius, Socinski, Mark A.

“…Abstract only e21087 Background: MYL-1402O (MYL) is a proposed biosimilar to bevacizumab reference product. A multicenter, double blind randomized, phase 3…”
Get full text